Core Viewpoint - The stock of Zhenbaodao has shown a mixed performance in recent trading sessions, with a slight increase on November 12, 2023, and a significant decline in revenue and profit for the first nine months of 2025 compared to the previous year [1][2]. Group 1: Stock Performance - On November 12, Zhenbaodao's stock rose by 2.16%, reaching a price of 11.85 CNY per share, with a trading volume of 48.31 million CNY and a turnover rate of 0.44%, resulting in a total market capitalization of 11.15 billion CNY [1]. - Year-to-date, Zhenbaodao's stock price has increased by 3.49%, while it has seen a 3.40% rise over the last five trading days, a 1.90% decline over the last 20 days, and a 6.40% drop over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on October 27, where it recorded a net buy of -4.88 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Zhenbaodao reported a revenue of 919 million CNY, reflecting a year-on-year decrease of 54.73%, and a net profit attributable to shareholders of -373 million CNY, a decline of 193.81% compared to the previous year [2]. - Cumulatively, since its A-share listing, Zhenbaodao has distributed a total of 1.302 billion CNY in dividends, with 356 million CNY distributed over the past three years [3]. Group 3: Company Overview - Zhenbaodao Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, and was established on October 28, 1996, with its shares listed on April 24, 2015. The company specializes in the research, production, and sales of traditional Chinese medicine, focusing on high-end formulations [1]. - The company's main revenue sources include sales of proprietary medicines (84.82%), purchased medicinal materials (7.13%), purchased pharmaceuticals (5.11%), and other income sources [1].

11月12日，东方生物盘中上涨2.10%，截至10:24，报27.75元/股，成交5771.05万元，换手率1.04%，总 市值55.94亿元。 资金流向方面，主力资金净流入581.66万元，特大单买入184.64万元，占比3.20%，卖出221.20万元，占 比3.83%；大单买入1529.76万元，占比26.51%，卖出911.54万元，占比15.80%。 东方生物今年以来股价跌5.39%，近5个交易日涨5.35%，近20日涨8.99%，近60日跌4.24%。 资料显示，浙江东方基因生物制品股份有限公司位于浙江省湖州市安吉县递铺街道阳光大道东段3787 号，成立日期2005年12月1日，上市日期2020年2月5日，公司主营业务涉及体外诊断产品研发、生产与 销售。主营业务收入构成为：体外诊断试剂97.99%，其他(补充)2.01%。 东方生物所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：基因测序、小盘、抗流 感、幽门螺杆概念、禽流感药物等。 截至9月30日，东方生物股东户数1.33万，较上期减少3.93%；人均流通股15170股，较上期增加4.09%。 2025年1月-9月，东方生物实现营 ...

分红方面，阳普医疗A股上市后累计派现7912.87万元。近三年，累计派现0.00元。 阳普医疗今年以来股价涨52.36%，近5个交易日涨2.69%，近20日涨9.65%，近60日跌7.89%。 资料显示，阳普医疗科技股份有限公司位于广东省珠海市横琴新区环岛东路3000号横琴国际商务中心 801-8017室,广州市经济技术开发区科学城开源大道102号，成立日期1996年8月19日，上市日期2009年 12月25日，公司主营业务涉及为临床检验实验室与临床护理提供以专业解决方案为依托的技术、产品和 服务。主营业务收入构成为：真空采血系统66.48%，试剂12.23%，软件产品及服务10.03%，检验服务 5.10%，其他产品3.23%，仪器2.81%，微生物转运系统0.12%。 阳普医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：微盘股、小盘、家庭医 生概念、抗流感、PPP概念等。 截至9月30日，阳普医疗股东户数2.85万，较上期增加16.74%；人均流通股9550股，较上期减少 14.34%。2025年1月-9月，阳普医疗实现营业收入3.49亿元，同比减少17.14%；归母净利润2404.4 ...

Core Viewpoint - Oriental Bio's stock price has shown fluctuations, with a recent increase of 2.05% and a year-to-date decline of 6.75%, indicating potential volatility in the market [1] Financial Performance - For the period from January to September 2025, Oriental Bio reported a revenue of 672 million yuan, reflecting a year-on-year growth of 2.16% [2] - The company experienced a net profit attributable to shareholders of -213 million yuan, which is an improvement of 18.89% compared to the previous period [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Oriental Bio was 13,300, a decrease of 3.93% from the previous period [2] - The average number of circulating shares per shareholder increased by 4.09% to 15,170 shares [2] Dividend Distribution - Since its A-share listing, Oriental Bio has distributed a total of 1.607 billion yuan in dividends, with 336 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.8 million shares, a decrease of 1.7001 million shares from the previous period [3] - Hong Kong Central Clearing Limited is the sixth largest shareholder, increasing its holdings by 139,400 shares to 1.4675 million shares [3] - The Southern Science and Technology Innovation Board 3-Year Open Mixed Fund maintained its holding of 780,900 shares, while the Medical Device ETF entered as a new shareholder with 757,900 shares [3]

Core Viewpoint - TaiLong Pharmaceutical has shown a significant stock price increase of 36.94% year-to-date, with recent trading activity indicating positive market sentiment and liquidity [1][2]. Financial Performance - For the period from January to September 2025, TaiLong Pharmaceutical reported a revenue of 1.187 billion yuan, representing a year-on-year decrease of 11.47%. The net profit attributable to shareholders was 25.33 million yuan, down 12.36% compared to the previous year [2]. - The company has cumulatively distributed 112 million yuan in dividends since its A-share listing, with 15.53 million yuan distributed over the last three years [3]. Stock Market Activity - As of November 11, TaiLong Pharmaceutical's stock price was 6.97 yuan per share, with a market capitalization of 4 billion yuan. The stock experienced a trading volume of 50.41 million yuan and a turnover rate of 1.28% [1]. - The stock has seen a net inflow of 2.36 million yuan from main funds, with large orders accounting for 22.95% of total purchases [1]. Shareholder Information - As of September 30, 2025, the number of shareholders for TaiLong Pharmaceutical was 40,400, a decrease of 1.08% from the previous period. The average number of tradable shares per shareholder increased by 1.09% to 14,190 shares [2]. - Among the top ten circulating shareholders, Guangfa Pension Index A held 2.9719 million shares, a decrease of 264,000 shares from the previous period, while Huatai-PineBridge CSI Traditional Chinese Medicine ETF entered as a new shareholder with 2.8616 million shares [3].

Core Viewpoint - Jilin Aodong's stock price has shown a significant increase this year, with a notable rise in net profit despite a decrease in revenue, indicating potential resilience in its business model and market positioning [1][2]. Financial Performance - As of September 30, 2025, Jilin Aodong reported a revenue of 1.64 billion yuan, a year-on-year decrease of 14.10%, while the net profit attributable to shareholders was 2.26 billion yuan, reflecting a year-on-year increase of 81.70% [2]. - The company's stock price increased by 28.67% year-to-date, with a 0.84% rise over the last five trading days, 6.18% over the last 20 days, and 13.91% over the last 60 days [1]. Shareholder Information - The number of shareholders decreased by 7.18% to 61,200, while the average circulating shares per person increased by 7.73% to 19,456 shares [2]. - The company has distributed a total of 4.664 billion yuan in dividends since its A-share listing, with 1.881 billion yuan distributed in the last three years [3]. Ownership Structure - As of September 30, 2025, the top ten circulating shareholders included Southern CSI 500 ETF, holding 13.93 million shares (a decrease of 317,900 shares), and Hong Kong Central Clearing Limited, holding 11.82 million shares (a decrease of 319,620 shares) [3].

Core Viewpoint - The information disclosure evaluation results for listed companies in 2024 show a significant decline in ratings for several companies, including 基蛋生物, which dropped from A to C compared to 2022 [1][2]. Group 1: Company Overview - 基蛋生物科技股份有限公司 is located in Nanjing, Jiangsu Province, and was established on March 8, 2002, with its listing date on July 17, 2017 [3]. - The company specializes in the research, production, and sales of in vitro diagnostic products, with 87.08% of its revenue coming from self-developed products and 12.92% from collaborative projects [3][4]. Group 2: Industry Classification - 基蛋生物 belongs to the pharmaceutical and biological industry, specifically in the medical device sector focusing on in vitro diagnostics [4]. - The company is associated with several concept sectors, including anti-influenza, small-cap stocks, Helicobacter pylori concept, monkeypox concept, and margin financing [4]. Group 3: Management Information - The current company secretary is Liu Cong, who has been in the position since December 18, 2020, and holds a master's degree [4][5]. - Liu Cong has previous experience as a credit manager at China Postal Savings Bank and has held various positions in corporate governance, obtaining qualifications from both Shenzhen and Shanghai stock exchanges [5].

Core Viewpoint - Kangyuan Pharmaceutical's stock has shown fluctuations with a year-to-date increase of 11.38%, but recent performance indicates a decline over the past 60 days by 10.82% [1] Group 1: Stock Performance - As of November 7, Kangyuan Pharmaceutical's stock price reached 15.17 CNY per share, with a trading volume of 73.44 million CNY and a turnover rate of 0.86% [1] - The stock has experienced a net outflow of 429,200 CNY from main funds, with large orders showing a buy of 11.98 million CNY and a sell of 12.21 million CNY [1] - Over the last five trading days, the stock has increased by 1.47%, while it has decreased by 1.56% over the last 20 days [1] Group 2: Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported a revenue of 2.343 billion CNY, representing a year-on-year decrease of 24.66% [2] - The net profit attributable to shareholders for the same period was 200 million CNY, down 44.10% compared to the previous year [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Kangyuan Pharmaceutical increased to 40,500, marking a rise of 17.20% [2] - The average number of circulating shares per person decreased by 14.68% to 13,969 shares [2] - The company has distributed a total of 949.8 million CNY in dividends since its A-share listing, with 345 million CNY distributed over the last three years [3]

Group 1 - The core viewpoint of the news is that Shuoshi Biotechnology has shown significant stock price performance and trading activity, with a year-to-date increase of 89.73% and a market capitalization of 6.525 billion yuan [1] - As of November 7, the stock price reached 77.80 yuan per share, with a trading volume of 35.4253 million yuan and a turnover rate of 0.55% [1] - The company has experienced net outflows of main funds amounting to 629,500 yuan, while large orders showed a mixed trend with total buy orders of 5.3918 million yuan and sell orders of 6.1871 million yuan [1] Group 2 - Shuoshi Biotechnology, established on April 12, 2010, specializes in the research, production, and sales of in vitro diagnostic products, with a revenue composition of 85.89% from testing reagents [2] - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics, and is involved in various concept sectors including small-cap stocks and high dividends [2] - For the period from January to September 2025, the company reported a revenue of 258 million yuan, a year-on-year decrease of 3.95%, and a net profit attributable to the parent company of 3.1517 million yuan, down 88.38% year-on-year [2] Group 3 - Since its A-share listing, Shuoshi Biotechnology has distributed a total of 1.37 billion yuan in dividends, with 285 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders decreased by 0.94% to 7,620, while the average circulating shares per person increased by 0.94% to 11,006 shares [2][3]

Core Viewpoint - Innotech's stock price has shown fluctuations, with a year-to-date decline of 8.23% but a recent recovery in the last five trading days, indicating potential market interest and volatility [2]. Company Overview - Innotech Biotechnology Co., Ltd. is located in Fengtai District, Beijing, and was established on February 6, 2006. The company went public on July 28, 2022, and specializes in the research, production, and sales of POCT rapid diagnostic products [2]. - The main revenue composition includes respiratory series (96.49%), other reagent series (2.99%), and preconception series (0.51%) [2]. - The company is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [2]. Financial Performance - For the period from January to September 2025, Innotech reported a revenue of 330 million yuan, representing a year-on-year decrease of 36.56%. The net profit attributable to the parent company was 131 million yuan, down 46.37% year-on-year [2]. - As of September 30, 2025, the total number of shareholders was 8,037, an increase of 10.57% from the previous period, while the average circulating shares per person decreased by 8.86% to 8,627 shares [2]. Stock Performance and Trading Activity - On November 7, Innotech's stock price increased by 2.15%, reaching 32.77 yuan per share, with a trading volume of 22.37 million yuan and a turnover rate of 1.00%. The total market capitalization stood at 4.489 billion yuan [1]. - The net inflow of main funds was 467,300 yuan, with significant selling activity amounting to 1.666 million yuan, indicating mixed investor sentiment [1]. Dividend Information - Since its A-share listing, Innotech has distributed a total of 152 million yuan in dividends [3]. Institutional Holdings - As of September 30, 2025, the medical device ETF (159883) was the ninth largest circulating shareholder, holding 498,000 shares as a new shareholder [3].